莫沙必利、乳果糖联合美常安治疗便秘型肠易激综合征的临床观察  

Clinical observation on the effect of mosapride and lactulose combined with Medilac-S on irritable bowel syndrome-constipation

作　　者：张红芳[1] 张新慧 Zhang Hongfang;Zhang Xinhui(The first affiliated hospital of Henan University,KaiFeng,Henan,475001,China;Luoyang Orthopedic-Traumatological hospital of Henan province(Henan provincial orthopedic hospital),Zhengzhou,Henan,450000,China)

机构地区：[1]河南大学第一附属医院,河南开封475001 [2]河南省洛阳正骨医院(河南省骨科医院),河南郑州450000

出　　处：《齐齐哈尔医学院学报》2023年第6期542-545,共4页Journal of Qiqihar Medical University

摘　　要：目的探讨莫沙必利、乳果糖联合美常安治疗对便秘型肠易激综合征(IBS-C)患者大便性状及血清血管活性肠肽(VIP)、一氧化氮(NO)水平的影响。方法选择2018年3月7日—2020年3月21日本院收治的67例便秘型IBS-C患者为研究对象,根据随机数表法分为对照组(33例,莫沙必利5 mg/次,每日3次、乳果糖治疗15 ml/次,每日2次)与观察组(34例,莫沙必利、乳果糖基础上联合美常安治疗500 g/次,每日3次)两组。比较两组患者分别治疗后的大便性状、不良反应,同时检测血清VIP、NO水平变化。结果两组患者一般资料(性别、年龄)比较,差异无统计学意义(P>0.05)。两组分别治疗8周后,观察组粪便正常者有28例(82.35%),对照组粪便正常者有18例(54.54%),组间差异具有统计学意义(P<0.05)。治疗前观察组与对照组的血清VIP水平无显著差异(P>0.05)。治疗后观察组血清VIP、NO水平与对照组相比明显低(P<0.05);观察组治疗后临床有效率为94.11%,明显高于对照组的72.72%(P<0.05);两组不良反应无明显差异(P>0.05)。结论莫沙必利、乳果糖、美常安三者有协同作用,联合治疗便秘型IBS-C有利于改善大便性状,降低血清VIP、NO水平,疗效确切,安全性高。Objective To analyze the effect of mosapride and lactulose combined with Medilac-S on stool characteristics and serum vasoactive intestinal peptide(VIP)and nitric oxide(NO)levels in patients with irritable bowel syndrome-constipation(IBS-C).Methods 67 patients with IBS-C those were treated in our hospital between March 7,2018 and March 21,2020 were prospectively selected as the study subjects.They were divided into control group(33 cases treated with mosapride at the dose of 5mg each time,3 times a day and lactulose 15mL each time,twice a day)and the observation group(34 cases treated with methapride and lactulose combined with Medilac-S at the dose of 500mg each time,3 times a day)according to the random number table method.The stool characteristics and adverse reactions were compared between the two groups,and changes in serum VIP and NO levels were detected.Results There was no significant difference in the general data(gender and age)between the two groups(P<0.05).After 8 weeks of treatment,the number of patients with normal stools in the observation group was 28(82.35%),and that in the control group was 18(54.54%),the difference between the two groups was statistically significant(P<0.05).There were no significant difference in serum VIP and NO levels between the observation group and the control group before treatment(P>0.05).Serum VIP and NO levels in the observation group were significantly lower than those in the control group after treatment(P<0.05).After treatment the clinical effective rate in the observation group(94.11%)was significantly higher than that(72.72%)in the control group(P<0.05).There was no significant difference in adverse reactions between the two groups(P>0.05).Conclusions Mosapride,lactulose,and Medilac-S presents a synergistic effect.Combination of the three of them in the treatment of IBS-C is beneficial to improve the stool characteristics and reduce serum VIP and NO levels,with definite effect and high safety.

关 键 词：莫沙必利 乳果糖 美常安 便秘型肠易激综合征 大便性状 

分 类 号：R574.4[医药卫生—消化系统]